Information For Authors
- Author Benefits Program
- Manuscript Submission Guidelines
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
Web-Based Electronic Manuscript Submission and Peer Review
We invite all authors to submit online any new manuscripts that are to be considered for publication. Please enter the following URL: http://mc.manuscriptcentral.com/space
New Space: The Journal of Space Entrepreneurship and Innovation is the only international peer-reviewed journal that is dedicated to the era of new space innovation.
This journal will facilitate new opportunities for collaboration in industry, academia, and government agencies and serve as the main platform in which the many goals identified in new space exploration, commercialization, and new space enterprises, is expedited.
As an independent and all-inclusive journal, New Space: The Journal of Space Entrepreneurship and Innovation features world-class peer-reviewed papers that cover the innovative and expanding applications emerging from the vast amount of new space-based disciplines. To date, many space exploration programs have greatly contributed to important mobile and medical devices, innumerable disruptive innovations, and have encouraged major advances in academia, government, and the private sector – this journal builds upon those initiatives and encourage the growth of rapidly expanding space initiatives and products that will benefit the way we live.
New Space: The Journal of Space Entrepreneurship and Innovation is the opportunity for new applications in space-based technologies and engineering to be discovered, identified, and applied.
New Space: The Journal of Space Entrepreneurship and Innovation publishes Research Articles, Reviews, invited Mini-Reviews, Rapid Communications, Hypothesis and Education Articles, and News and Views contributions.
The review process for all manuscripts will be initiated when authors submit (a) a “.doc” or a “.rtf” or LaTeX file that contains the manuscript, references, tables, and figure legends, and (b) a single high-resolution “.tif” or “.eps” file of each figure. (Note that LaTeX cannot be used for printing if the article is accepted—see detailed note about LaTeX below.) Guidelines for preparing the various components of the contribution, including the preparation of high-resolution digital figure files, are provided below. Incomplete or improperly formatted contributions will be returned to the authors unread.
Manuscripts are judged on the basis of significance, originality, quality and clarity of presentation, and appropriateness of the subject matter. The decision regarding publication is the responsibility of the Editors, based on the recommendations of the Referees, Editorial Board Members, and Guest Editors.
Manuscripts. Manuscripts should be double-spaced and formatted for US Letter (8.5 x 11 inches) page size with 1.5-inch margins on top, bottom, and sides. Times or Times New Roman (12 point) is the preferred font. Manuscript pages should be numbered consecutively.
Manuscripts should be organized as follows: On the first page give the title of the article, the full names and institutional affiliations of all authors, the name (with complete address, phone and fax numbers, and e-mail address) to whom correspondence should be directed, and a running title of no more than 40 characters (including spaces). Supply an Abstract of about 200 words, stating the aims, results, and conclusions drawn from the study, and 3–6 key words or phrases. The Abstract page should be followed by the remainder of the manuscript organized with headings to distinguish the Introduction, Materials and Methods, Results, Discussion, Conclusions and/or Implications, Acknowledgments, References, Tables, Figure Legends, and Figures. Results and Discussion should be separate manuscript sections.
PUBLICATION ETHICS AND MALPRACTICE STATEMENTS
Ethical Considerations in the Conduct and Reporting of Research: Protection of Human Subjects and Animals in Research
Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.
Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements.
Definitions of Scientific Misconduct
Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).
Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:
- Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.
Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
Material failure to comply with legislative and regulatory requirements affecting research:
Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
- Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
- Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.
- Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.
Responding to Allegations of Possible Misconduct
The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.
When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.
Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.
If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.
All allegations will be kept confidential.
Disclosure statement. Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.”
In this portion of the article, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the article is being reviewed and will not influence the editorial decision.
Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance.
If no conflicts exist, the authors must state “No competing financial interests exist.”
It is recommended that authors review the style and clarity of their manuscript with colleagues before submission to ensure its consideration for publication and avoid delay in review and publication processing. Manuscripts may be edited if needed to ensure clear grammatical English usage. The editors welcome suggestions concerning potential reviewers that serve on the Editorial Board of
New Space: The Journal of Space Entrepreneurship and Innovation as well as those from the international scientific community.
LETTERS TO THE EDITOR(S):
Letters to the Editor(s) are welcomed, but with a 500-word limit and no more than one (1) table OR figure, and with a maximum of four (4) references.
References in text should be numerical using superscripted numbers. Do not include brackets or parentheses. Text references must be supplied in sequence for all tables and figures. Double space all references. Number each reference consecutively in the manuscript in order of citation. Number references consecutively (not alphabetically) in the reference section. Abbreviations of journal titles should follow MEDLINE. Accuracy of citation is the responsibility of the authors; remember that inaccurate references are highly frustrating to the reader, the cited author, and indexing services.
Gloria A, Ronca D, Russo T, et al. Technical features and criteria in designing fiber-reinforced composite materials: From the aerospace and aeronautical field to biomedical applications. J Appl Biomater Biomech. 2011;9(2):151-63.
Anderson J. Fundamentals of Aerodynamics (Series in Aeronautical and Aerospace Engineering). New York: McGraw Hill, 2010.
If a work is in press, give the journal in which it is to be published along with the words “in press.” Work that has not yet been accepted for publication must be indicated in the article as a personal communication or as unpublished data.
Tables and Illustrations
Present each table with its caption on a separate page of the manuscript. Use Arabic numerals to number tables. Information given in the text should not be repeated in tables unless advised by the editors. Tables should not be used for data that can be given in the text in one or two sentences. Tables must be numbered in the order cited in the text. The typesetter will determine the final format of manuscript tables.
Figure legends should be supplied for each illustration. All figure legends should be numbered consecutively, typed double-spaced, and begun with a boldface FIG.1. (2, 3, etc), though the rest of the caption should be in regular type. If there are several images in the figure—a, b, c, etc.—these should be placed in parentheses and put in boldface on their first occurrence. Figures must be numbered in the order cited in the text. Figures will be reproduced in the journal at column (8 cm) or page (16.5 cm) width. Illustration text should be no smaller than 10 point Helvetica at column width.
High-resolution digital files of photographs or line art must be uploaded onto Manuscript Central. Each figure should be submitted as a separate file in “.tif” or “.eps” file format (byte order for Macintosh) at the final print size (8.5 or 16 cm width) and resolution (see below). Figure filenames must include the last name of the first author, figure number, and format extension (e.g., CadyFig1.tif). Figure resolution can be confirmed using Adobe Photoshop by opening the “tif” file, selecting image, image size, and print size. Authors should avoid artificially increasing the image resolution using Adobe Photoshop, which is possible by checking “resample image” when viewing the print size. Resolution and format requirements for images at the print size: line art (bar scales, schematic drawings, etc.) should be no less than 1,200 dpi; photographs no less than 300 dpi (same as ppi in Adobe Photoshop). Black and white (halftone) photographs should be saved as ‘‘grayscale’’ images, and color photographs as “cymk” images.
Figures/images should be presented according to these guidelines:
- Do not include any illustrations as part of your text file.
- Do not prepare any figures in Word as they are not workable.
- Line illustrations must be submitted at 900 DPI.
- Halftones and color photos should be submitted at 300 DPI.
- Please submit only TIFF, EPS or PDF files.
- Color art must be saved as CYMK not RGB or INDEX. If RGB files are submitted, the files will be converted to CYMK, and some slight color variation may occur.
- PowerPoint or Excel files are not acceptable file types for uploading to Manuscript Central.
A Note about LaTeX. Though LaTeX files can be submitted to the Journal and sent out for review, we require the final manuscript be in the “.doc” format. Once a manuscript in LaTeX format has been recommended for publication, it will be the author’s responsibility to have that version of the manuscript converted, scanned, or retyped into MS Word as a “.doc” file so that it can be ready for production. Should the article contain complicated equations or formulas, the “.doc” version of the manuscript should be marked to show where they should be inserted and a hard copy list of all equations and formulas forwarded to the Editorial Office.
The author must obtain permission whenever it is required in conjunction with the reproduction of copyrighted material such as figures and tables. Written permission must be obtained by the author from the publisher of the journal or book concerned; and, if required by the original publisher, the figure or table legend should indicate the original publication. The publication from which the figure or table is taken must also be listed in the reference section. All permission listings must be obtained prior to typesetting the manuscript; they cannot be entered on proofs. Manuscripts submitted to this journal must not be under consideration elsewhere.
Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: 914-740-2100; fax: 914-740-2101. E-mail: email@example.com Online: www.liebertpub.com
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email firstname.lastname@example.org.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email email@example.com or visit Liebert Open Access for more information.